The KRAS-variant is one of the first discovered members of a new class of genetic markers that predict increased cancer risk and unique treatment response to cancer therapy. The biology of the KRAS-variant affords great promise for both preventing and curing cancer in individuals with this inherited mutation.

 

Women’s Cancer Risk

Women with the KRAS-variant have up to a six-fold increased risk of developing breast and ovarian cancer, as well as an increased risk of non-small cell lung cancer. New data indicates that changing estrogen levels and withdrawal increases or triggers cancer risk for women with this genetic mutation. In addition, women with the KRAS-variant appear to be at a significantly higher risk of multiple primary cancer, including multiple primary breast cancer. Knowing a woman’s KRAS-variant status is an additional piece of information to help direct decisions for screening, risk reduction and estrogen management.

Personalized Medicine

The KRAS-variant has been shown to significantly predict which medicines will and will not work for cancer patients. This information can subgroup patients into responders or non-responders to therapies being used today as standard of care. Knowing a patient’s KRAS-variant status affords the opportunity to personalize treatment and ultimately get better results.

Radiogenomics

Currently, there are no biomarkers used to identify patients who may be over-sensitive to radiation therapy, which is a treatment used for over 75% of cancer patients. MiraDx is developing a panel of such biomarkers, including the KRAS-variant, as well as preparing individual patient testing to diagnose those with ATM.

FROM THE DECEMBER 2014 ISSUE

discover-mag

The Little-Known Genetic Mutation Behind Many Aggressive Cancers

Despite the dangers of the KRAS-variant mutation, few doctors have heard of it. But one researcher is trying to change that.

Read more

Are you interested in ongoing studies about the KRAS-variant?

Visit our sister non-profit Mirakind, and register for their newsletter to receive updates.